Valley Cottage, NY -- (SBWIRE) -- 12/20/2017 -- Improving healthcare infrastructure across several countries and regions, coupled with availability of well-developed manufacturing units, facilitates the growth of medical device businesses. The changing attitude of patients towards treatment of generic diseases has indicated a significant rise in preference for self-administration devices such as auto-injectors. Promoting this notion, auto-injectors continue to gain prominence not just as an alternative route for drug delivery but also as point-of-care devices in homecare settings. Future Market Insights recently published its report on the global market for auto-injectors, which projects that by the end of 2026, more than US$ 6,800 Mn worth of auto-injectors will sold globally. Currently valued at US$ 1,673.7 Mn, the global auto-injectors market is being projected to exhibit an impressive value CAGR of 15.1%.
Higher Demand for Auto-Injectors in Treatment of Anaphylaxis
Factor that is inducing growth in demand for auto-injectors is the prevalence of multiple sclerosis and anaphylaxis. Notable disease monitoring associations from across the globe are predicting that these disorders are less likely to cease their occurrence rate among geriatric populations, which is incidentally boosting the demand for auto-injectors. In 2016, anaphylaxis as a disease indication accounted for an estimated US$ 1,500 Mn of global auto-injector revenues. Through 2026, almost nine out of ten auto-injectors sold globally are likely to be used for treating anaphylaxis. Meanwhile, auto-injectors sold for treatment of multiple sclerosis will register a marginal rise through the forecast period. And, revenues amassed from sales of auto-injectors for rheumatoid arthritis are expected to showcase highest CAGR of 18.3%.
Parallel to their rising demand, the global supply of auto-injectors is also expected to propel by the end of 2026. Increased development of biologics, their use in production of advanced drug delivery devices, reduction of manufacturing prices, and additional cost-savings conferred by technological advancements, are all collectively bolstering the global production of auto-injectors. The report has profiled leading players in the global auto-injectors market, which include Amgen Inc., Novartis AG, Sanofi, Pfizer, Inc., Becton, Dickson and Company, Mylan NV, Bayer AG, Eli Lily and Company, Janssen Global Services, LLC, and Antares Pharma, Inc.
Request report toc@ https://www.futuremarketinsights.com/reports/auto-injectors-market/toc